Adverum Biotechnologies (ADVM)

• Market cap: $92.8M
• 1 day: -0.24%
• 5 days: -4.52%
• 1 month: -6.84%
• 3 months: 76.57%
• 6 months: 29.45%
• Year to date: -12.08%
• 1 year: -46.45%
• 5 years: -96.13%
• 10 years: -94.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Employees: 155